Cash, cash equivalents and short-term investments were $71.8 million as of June 30, 2025. Based on its current operating plans, the Company expects that its cash, cash equivalents and short-term investments will be sufficient to fund operations into 2027.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma Expands Board, Appoints New Director
- Connect Biopharma announces expansion of board, appoints Schoeneck as director
- Northland starts Connect Biopharma at Outperform on chance to define new class
- Connect Biopharma initiated with an Outperform at Northland
- Connect Biopharma Ends ADS Agreement with Deutsche Bank